Sign in
Stories
Aprea Therapeutics Advances WEE1 Inhibitor
Share
Advancements in Cancer Treatment and Mar...
AnaMar Receives Orphan Drug Designation ...
Bayer's BAY 2927088 Breakthrough Therapy...
4D Molecular Therapeutics Raises $300 Mi...
AI-Powered Cancer Drug Trials
ANJESO Drug Insight and Market Forecast
Overview
API
Aprea Therapeutics submits IND application for WEE1 kinase inhibitor APR-1051, planning clinical testing in 2024.
Ask a question
How might the submission of APR-1051's IND application impact the competitive landscape in the field of WEE1 kinase inhibitors?
In what ways could Aprea's focus on solid tumor indications shape the future of WEE1 inhibitors in cancer treatment?
What are the potential implications of Aprea's decision to commence clinical testing in the first half of 2024?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage